Postprocedural serum sLOX-1 levels are significantly associated with the risk of ISR and the severity of lumen loss in patients with stable coronary artery disease undergoing primary PCI. These results suggested that postprocedural serum sLOX-1 levels might be useful for the detection and risk assessment of ISR after PCI.

Serum sLOX-1 levels are associated with the presence and severity of angiographic coronary artery disease in patients with metabolic syndrome Abstract Purpose: Patients with metabolic syndrome are at high-risk for development of atherosclerosis and cardiovascular events. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1(sLOX-1) is associated with coronary artery disease (CAD) and metabolic disorders. We sought to assess whether serum sLOX-1 levels are correlated with the presence and severity of CAD in patients with metabolic syndrome (MetS) undergoing coronary angiography.Methods: Serum sLOX-1 levels were measured in 112 consecutive patients with MetS, undergoing coronary angiography for the evaluation of CAD. e severity of CAD was assessed by angiographic Gensini score system.Results: Serum sLOX-1 levels were signi cantly higher in MetS patients with CAD (n=69) than in those without CAD (n=43) (0.925 [range 0.137 to 1.432] ng/ml vs. 0.207 [range 0.063 to 0.774] ng/ml, P<0.01). Multivariate logistic regression analysis revealed that serum sLOX-1 level was independently associated with the presence of CAD (odds ratio 2.489, 95% con dence interval 1.290-4.802; P<0.01). Serum sLOX-1 levels were positively correlated with the Gensini score (ρ: 0.394, P<0.01) a er adjusting for other clinical characteristics.Conclusions: High sLOX-1 levels are associated with the presence and severity of CAD in patients with MetS. e measurement of serum sLOX-1may be potentially useful in predicting the presence and severity of CAD in patients with MetS. ORIGINAL RESEARCH © 2010 CIMClin In E398 Many epidemiological and clinical studies have con rmed the association between metabolic syndrome (MetS) and increased risk for coronary artery disease (CAD), which is the leading cause of mortality worldwide [1,2]. Morbidity and mortality from CAD are higher in patients with MetS [1]; therefore, early assessment of the risk of CAD in patients with MetS is desirable because it could lead to improved patient or physician adherence to risk-reducing behaviors or interventions and improve clinical outcomes. Lectin-like oxidized low-density lipoprotein receptor-1(LOX-1), a type II membrane glycoprotein, was initially identi ed as the major receptor for oxidized low-density lipoprotein (ox-LDL) in endothelial cells (ECs) and was later found also to have an inducible expression in macrophages and vascular smooth muscle cells (VSMCs) [3,4]. Like many cell-surface receptors with a single transmembrane domain, LOX-1 can be proteolytically cleaved at its membrane proximal extracellular domain and released as a soluble form (sLOX-1) [5]. e level of circulating sLOX-1 may re ect the expression of LOX-1 [6], and is increasing viewed as a biomarker for CAD. Circulating sLOX-1 levels are elevated in patients with acute coronary syndrome (ACS) [7] and are associated with in ammatory makers and oxidative stress markers in patients with CAD [8,9]. More recently, a prospective study has demonstrated that higher LOX index values are associated...